Lv338
238 积分 2026-05-15 加入
Consolidative therapy for PSMA-avid lesions after 3 cycles of apalutamide plus androgen deprivation in metastatic hormone-sensitive prostate cancer: A prospective phase 2 single-arm trial
1小时前
已完结
The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [(177)Lu]Lu-PSMA-617: a WARMTH multicentre study
2天前
已完结
Health-related quality of life, pain, and symptomatic skeletal events with [(177)Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial
7天前
已完结
PSMAfore: A phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer
7天前
已完结
Current and future directions in theranostics for neuroendocrine prostate cancer
7天前
已完结
Synthesis and preclinical evaluation of a heterodimeric radioligand targeting fibroblast activation protein and integrin-α(v)β(3)
8天前
已完结
A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine
8天前
已完结
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers
8天前
已完结
Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene
8天前
已完结
Expression of prostate-specific membrane antigen in normal and malignant human tissues
8天前
已完结
皖公网安备34019202002308
